Combivir (AZT/3TC)
| Brand Name: |
Combivir |
| Generic Name: |
Zidovudine and lamivudine, AZT and 3TC |
| Adult Single Dose: |
One tablet containing 300 mg AZT and 150 mg 3TC
(twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Combivir (AZT/3TC) (September 13, 2012)
From AIDSinfo
- Combivir (Zidovudine + Lamivudine) (May 16, 2012)
To read PDF, click here.
From AIDS InfoNet
- Combivir (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Combivir (AZT/3TC) (PDF) (November 2011)
From ViiV Healthcare
- Combivir (AZT + Epivir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Combivir (AZT/3TC) (October 19, 2006)
From AIDS Treatment Data Network
- Drug Interactions: Combivir (August 2004)
From Project Inform
- GlaxoSmithKline Alerts Patients, Pharmacists and Physicians to Watch for Third-Party Tampering That Incorrectly Labels Ziagen as Combivir (May 10, 2002)
From U.S. Food and Drug Administration
- FDA Approves First Combination Drug for AIDS (September 29, 1997)
Combivir (combination of zidovudine and lamivudine) receives traditional approval for treating AIDS and HIV infection.
From U.S. Food and Drug Administration
News
Research
- Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Zidovudine/Lamivudine Inferior as First-Line NRTI Backbone (August 15, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Aurobindo Receives Tentative FDA Approval to Produce Generic Version of Combivir for PEPFAR (July 11, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aurobindo Pharma Receives Tentative FDA Approval to Produce Generic Stavudine for PEPFAR (July 5, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here.
From U.S. National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
